Advertisement

International Journal of Clinical Pharmacy

, Volume 35, Issue 3, pp 297–302 | Cite as

New and old anti-thrombotic treatments for patients with atrial fibrillation

  • Andrea MessoriEmail author
  • Dario Maratea
  • Valeria Fadda
  • Sabrina Trippoli
Commentary

Impacts on practice

  • The effectiveness of new oral anticoagulants in atrial fibrillation is extensively being studied, but also innovative medical devices aimed at this disease condition need to be evaluated (e.g. Watchman).

  • Regardless of the type of treatment, the same end-points (stroke or systemic embolism, death from any cause) have been assessed in clinical trials so that meta-analysis techniques can be applied.

  • Our study employed network meta-analysis to synthetise the effectiveness data of warfarin, new oral anticoagulants, and Watchman and showed the potential advantages of the new treatments as well as the economic implications in terms of budget impact.

Introduction

Patients with non-valvular atrial fibrillation are at risk for stroke and can therefore require chronic treatment. While warfarin has long been the standard of care, the new oral anticoagulants (namely, dabigatran, rivaroxaban, and apixaban) have recently been proposed as an alternative. One advantage of these new...

Keywords

Atrial fibrillation Budget impact Cost-effectiveness Dabigatran Left atrial appendage closure Network meta-analysis Watchman Oral anticoagulants 

Notes

Funding

None.

Conflicts of interest

None.

References

  1. 1.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD. RE-LY steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.PubMedCrossRefGoogle Scholar
  2. 2.
    Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(534):42. (Erratum in Lancet. 2009 Nov 7;374(9701):1596).Google Scholar
  5. 5.
    Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the continued access registry. Circulation. 2011;123(4):417–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Holmes DR Jr, Fountain R. Stroke prevention in atrial fibrillation: WATCHMAN versus warfarin. Expert Rev Cardiovasc Ther. 2009;7(7):727–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Fadda V, Maratea D, Trippoli S, Messori A. Network meta-analysis. Results can be summarised in a simple figure. Br Med J. 2011;342:d1555.CrossRefGoogle Scholar
  8. 8.
    Passaro D, Fadda V, Maratea D, Messori A. Anti-platelet treatments in acute coronary syndrome: simplified network meta-analysis. Int J Cardiol. 2011;150(3):364–7.PubMedCrossRefGoogle Scholar
  9. 9.
    ITC software. Canadian Agency for Drugs and Technologies in Health, Indirect Treatment Comparison software, Ottawa, Ontario, Canada.Google Scholar
  10. 10.
    Maratea D, Messori A. the WEF-E study group. Nationwide prediction of future expenditure for protease inhibitors in chronic hepatitis C. Dig Liver Dis. 2012;44(1):86–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Maratea D. Economic consequences of approval extensions: the case of rituximab (published 26 May 2011). eBMJ, available at http://www.bmj.com/content/338/bmj.b67?tab=responses.
  12. 12.
    Gage BF. Cost of dabigatran for atrial fibrillation. BMJ. 2011;31(343):d6980. doi: 10.1136/bmj.d6980.CrossRefGoogle Scholar
  13. 13.
    Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ. 2011;343:d6333.PubMedCrossRefGoogle Scholar
  14. 14.
    Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012;108(3).Google Scholar
  15. 15.
    Rasmussen LH, Larsen TB, Graungaard T, Skjøth F, Lip GY. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ. 2012;5(345):e7097. doi: 10.1136/bmj.e7097.CrossRefGoogle Scholar
  16. 16.
    Fadda V, Maratea D, Passaro D, Trippoli S. “Metanalisi a rete” o “network meta-analysis”, un nuovo strumento di analisi delle evidenze. Esempi di applicazione. Bollettino SIFO 2011;57(Jan–Feb issue): doi  10.1704/751.8491.
  17. 17.
    Anonymous. Epidemiologia della fibrillazione atriale dati dalla letteratura scientifica e dalle fonti informative disponibili. Ser. Estratto da IES, bollettino informativo del sistema epidemiologico regionale del veneto - n.4, dicembre 2009; pp. 3–6.Google Scholar
  18. 18.
    Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy (PREVAIL) http://www.clinicaltrials.gov/ct2/show/NCT01182441.
  19. 19.
  20. 20.
    Schulman S. Is the network meta-analysis bringing us closer to the truth? Insights from recent antithrombotic drug data. Thromb Haemost. 2012;108:872–5. doi: 10.1160/TH12-10-0730.PubMedCrossRefGoogle Scholar
  21. 21.
    Messori A, Fadda V, Maratea D, Trippoli S. Does network meta-analysis generate any new knowledge? Thromb Haemost. 2012;109(2). doi: 10.1160/TH12-10-0749.
  22. 22.
    Solomon MD, Ullal AJ, Hoang DD, Freeman JV, Heidenreich P, Turakhia MP. Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation. J Cardiovasc Med. 2012;13(2):86–96.CrossRefGoogle Scholar
  23. 23.
    Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG), Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S; Document Reviewers, Vardas P, Al-Attar N, Alfieri O, Angelini A, Blömstrom-Lundqvist C, Colonna P, De Sutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidbüchel H, Heldal M, Kristensen SD, Kolh P, Le Heuzey JY, Mavrakis H, Mont L, Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U, Van Gelder IC, Verheugt FW. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33(21):2719–47.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Andrea Messori
    • 1
    Email author
  • Dario Maratea
    • 1
  • Valeria Fadda
    • 1
  • Sabrina Trippoli
    • 1
  1. 1.HTA UnitArea Vasta Centro Toscana, ESTAV, Regional Health SystemPratoItaly

Personalised recommendations